25 results on '"Shamji, M.H."'
Search Results
2. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
- Author
-
Sousa-Pinto, B., Louis, R., Anto, J.M., Amaral, R., Sá-Sousa, A., Czarlewski, W., Brussino, L., Canonica, G.W., Chaves Loureiro, C., Cruz, A.A., Gemicioglu, B., Haahtela, T., Kupczyk, M., Kvedariene, V., Larenas-Linnemann, D.E., Okamoto, Y., Ollert, M., Pfaar, O., Pham-Thi, N., Puggioni, F., Regateiro, F.S., Romantowski, J., Sastre, J., Scichilone, N., Taborda-Barata, L., Ventura, M.T., Agache, I., Bedbrook, A., Becker, S., Bergmann, K.C., Bosnic-Anticevich, S., Bonini, M., Boulet, L.-P., Brusselle, G., Buhl, R., Cecchi, L., Charpin, D., de Blay, F., Del Giacco, S., Ivancevich, J.C., Jutel, M., Klimek, L., Kraxner, H., Kuna, P., Laune, D., Makela, M., Morais-Almeida, M., Nadif, R., Niedoszytko, M., Papadopoulos, N.G., Papi, A., Patella, V., Pétré, B., Rivero Yeverino, D., Robalo Cordeiro, C., Roche, N., Rouadi, P.W., Samolinski, B., Savouré, M., Shamji, M.H., Sheikh, A., Suppli Ulrik, C., Usmani, O.S., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Fonseca, J.A., Costa, E.M., and Bousquet, J.
- Published
- 2023
- Full Text
- View/download PDF
3. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations
- Author
-
Jutel M., Torres M.J., Palomares O., Akdis C.A., Eiwegger T., Untersmayr E., Barber D., Zemelka-Wiacek M., Kosowska A., Palmer E., Vieths S., Mahler V., Canonica W.G., Nadeau K., Shamji M.H., Agache I., Akdis M., Khaitov M., Alvarez-Perea A., Alvaro-Lozano M., Atanaskovic-Markovic M., Backer V., Barbaud A., Bavbek S., de Blay F., Bonini M., Bonini S., van Boven J.F.M., Brockow K., Cazzola M., Chatzipetrou A., Chivato T., Cianferoni A., Corren J., Cristoph-Caubet J., Dunn-Galvin A., Ebisawa M., Firinu D., Gawlik R., Gelincik A., del Giacco S., Mortz C.G., Jurgen Hoffmann H., Hoffmann-Sommergruber K., Klimek L., Knol E., Lauerma A., de Llano L.P., Matucci A., Meyer R., Moreira A., Morita H., Patil S.U., Pfaar O., Popescu F.-D., del Pozo V., Price O.J., van Ree R., Fernandez-Rivas M., Rogala B., Romano A., Santos A., Sediva A., Skypala I., Smolinska S., Sokolowska M., Sturm G., Vultaggio A., Walusiak-Skorupa J., Worm M., University of Zurich, Shamji, Mohamed H, Agache, Ioana, Ear, Nose and Throat, Experimental Immunology, AII - Inflammatory diseases, APH - Global Health, APH - Personalized Medicine, Groningen Research Institute for Asthma and COPD (GRIAC), Value, Affordability and Sustainability (VALUE), and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Subjects
DOWN-REGULATION ,COVID-19 Vaccines ,Immunology ,610 Medicine & health ,IMMUNOGENICITY ,10183 Swiss Institute of Allergy and Asthma Research ,VACCINES ,INFECTION ,Hypersensitivity ,Humans ,Immunology and Allergy ,SARS ,2403 Immunology ,Biological Products ,T-CELL RESPONSES ,SARS-CoV-2 ,IMMUNE-RESPONSES ,Vaccination ,AIT ,Allergens ,Immunoglobulin E ,allergy ,Asthma ,mRNA vaccines ,biologicals ,Desensitization, Immunologic ,SAFETY ,2723 Immunology and Allergy ,immunotherapy ,INFLUENZA VACCINATION ,Covid-19 ,SEVERE ASTHMA ,allergen - Abstract
Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.
- Published
- 2022
4. Biomarker der AIT: Modelle zur Vorhersage der Wirksamkeit
- Author
-
Tan, T.J., primary, Delgado-Dolset, M.I., additional, Escribese, M.M., additional, Barber, D., additional, Layhadi, J.A., additional, and Shamji, M.H., additional
- Published
- 2022
- Full Text
- View/download PDF
5. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations
- Author
-
Jutel, M. Torres, M.J. Palomares, O. Akdis, C.A. Eiwegger, T. Untersmayr, E. Barber, D. Zemelka-Wiacek, M. Kosowska, A. Palmer, E. Vieths, S. Mahler, V. Canonica, W.G. Nadeau, K. Shamji, M.H. Agache, I. Akdis, M. Khaitov, M. Alvarez-Perea, A. Alvaro-Lozano, M. Atanaskovic-Markovic, M. Backer, V. Barbaud, A. Bavbek, S. de Blay, F. Bonini, M. Bonini, S. van Boven, J.F.M. Brockow, K. Cazzola, M. Chatzipetrou, A. Chivato, T. Cianferoni, A. Corren, J. Cristoph-Caubet, J. Dunn-Galvin, A. Ebisawa, M. Firinu, D. Gawlik, R. Gelincik, A. del Giacco, S. Mortz, C.G. Jürgen Hoffmann, H. Hoffmann-Sommergruber, K. Klimek, L. Knol, E. Lauerma, A. de Llano, L.P. Matucci, A. Meyer, R. Moreira, A. Morita, H. Patil, S.U. Pfaar, O. Popescu, F.-D. del Pozo, V. Price, O.J. van Ree, R. Fernández-Rivas, M. Rogala, B. Romano, A. Santos, A. Sediva, A. Skypala, I. Smolinska, S. Sokolowska, M. Sturm, G. Vultaggio, A. Walusiak-Skorupa, J. Worm, M.
- Abstract
Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals. © 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
- Published
- 2022
6. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper
- Author
-
Pfaar, O. Agache, I. Bergmann, K.-C. Bindslev-Jensen, C. Bousquet, J. Creticos, P.S. Devillier, P. Durham, S.R. Hellings, P. Kaul, S. Kleine-Tebbe, J. Klimek, L. Jacobsen, L. Jutel, M. Muraro, A. Papadopoulos, N.G. Rief, W. Scadding, G.K. Schedlowski, M. Shamji, M.H. Sturm, G. van Ree, R. Vidal, C. Vieths, S. Wedi, B. Gerth van Wijk, R. Frew, A.J.
- Abstract
The placebo (Latin “I will please”) effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients’ expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double-blind, placebo-controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2021
7. Management of anaphylaxis due to COVID-19 vaccines in the elderly
- Author
-
Bousquet, J. Agache, I. Blain, H. Jutel, M. Ventura, M.T. Worm, M. Del Giacco, S. Benetos, A. Bilo, B.M. Czarlewski, W. Abdul Latiff, A.H. Al-Ahmad, M. Angier, E. Annesi-Maesano, I. Atanaskovic-Markovic, M. Bachert, C. Barbaud, A. Bedbrook, A. Bennoor, K.S. Berghea, E.C. Bindslev-Jensen, C. Bonini, S. Bosnic-Anticevich, S. Brockow, K. Brussino, L. Camargos, P. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Carriazo, A. Casale, T. Caubet, J.-C. Cecchi, L. Cherubini, A. Christoff, G. Chu, D.K. Cruz, A.A. Dokic, D. El-Gamal, Y. Ebisawa, M. Eberlein, B. Farrell, J. Fernandez-Rivas, M. Fokkens, W.J. Fonseca, J.A. Gao, Y. Gavazzi, G. Gawlik, R. Gelincik, A. Gemicioğlu, B. Gotua, M. Guérin, O. Haahtela, T. Hoffmann-Sommergruber, K. Hoffmann, H.J. Hofmann, M. Hrubisko, M. Illario, M. Irani, C. Ispayeva, Z. Ivancevich, J.C. Julge, K. Kaidashev, I. Khaitov, M. Knol, E. Kraxner, H. Kuna, P. Kvedariene, V. Lauerma, A. Le, L.T.T. Le Moing, V. Levin, M. Louis, R. Lourenco, O. Mahler, V. Martin, F.C. Matucci, A. Milenkovic, B. Miot, S. Montella, E. Morais-Almeida, M. Mortz, C.G. Mullol, J. Namazova-Baranova, L. Neffen, H. Nekam, K. Niedoszytko, M. Odemyr, M. O’Hehir, R.E. Okamoto, Y. Ollert, M. Palomares, O. Papadopoulos, N.G. Panzner, P. Passalacqua, G. Patella, V. Petrovic, M. Pfaar, O. Pham-Thi, N. Plavec, D. Popov, T.A. Recto, M.T. Regateiro, F.S. Reynes, J. Roller-Winsberger, R.E. Rolland, Y. Romano, A. Rondon, C. Rottem, M. Rouadi, P.W. Salles, N. Samolinski, B. Santos, A.F. S Sarquis, F. Sastre, J. M. G. A. Schols, J. Scichilone, N. Sediva, A. Shamji, M.H. Sheikh, A. Skypala, I. Smolinska, S. Sokolowska, M. Sousa-Pinto, B. Sova, M. Stelmach, R. Sturm, G. Suppli Ulrik, C. Todo-Bom, A.M. Toppila-Salmi, S. Tsiligianni, I. Torres, M. Untersmayr, E. Urrutia Pereira, M. Valiulis, A. Vitte, J. Vultaggio, A. Wallace, D. Walusiak-Skorupa, J. Wang, D.-Y. Waserman, S. Yorgancioglu, A. Yusuf, O.M. Zernotti, M. Zidarn, M. Chivato, T. Akdis, C.A. Zuberbier, T. Klimek, L.
- Abstract
Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2021
8. The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective
- Author
-
Bousquet, J. Jutel, M. Pfaar, O. Fonseca, J.A. Agache, I. Czarlewski, W. Bachert, C. Bergmann, K.C. Cruz, A.A. Klimek, L. Kvedariene, V. Larenas-Linnemann, D.E. Papadopoulos, N.G. Patella, V. Regateiro, F.S. Scichilone, N. Shamji, M.H. Sheikh, A. Valovirta, E. Ventura, M.-T. Zuberbier, T.
- Abstract
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology. © 2021 American Academy of Allergy, Asthma & Immunology
- Published
- 2021
9. 2019 ARIA Care pathways for allergen immunotherapy
- Author
-
Bousquet, J. Pfaar, O. Togias, A. Schünemann, H.J. Ansotegui, I. Papadopoulos, N.G. Tsiligianni, I. Agache, I. Anto, J.M. Bachert, C. Bedbrook, A. Bergmann, K.-C. Bosnic-Anticevich, S. Bosse, I. Brozek, J. Calderon, M.A. Canonica, G.W. Caraballo, L. Cardona, V. Casale, T. Cecchi, L. Chu, D. Costa, E. Cruz, A.A. Czarlewski, W. Durham, S.R. Du Toit, G. Dykewicz, M. Ebisawa, M. Fauquert, J.L. Fernandez-Rivas, M. Fokkens, W.J. Fonseca, J. Fontaine, J.-F. Gerth van Wijk, R. Haahtela, T. Halken, S. Hellings, P.W. Ierodiakonou, D. Iinuma, T. Ivancevich, J.C. Jacobsen, L. Jutel, M. Kaidashev, I. Khaitov, M. Kalayci, O. Kleine Tebbe, J. Klimek, L. Kowalski, M.L. Kuna, P. Kvedariene, V. La Grutta, S. Larenas-Linemann, D. Lau, S. Laune, D. Le, L. Lodrup Carlsen, K. Lourenço, O. Malling, H.-J. Marien, G. Menditto, E. Mercier, G. Mullol, J. Muraro, A. O’Hehir, R. Okamoto, Y. Pajno, G.B. Park, H.-S. Panzner, P. Passalacqua, G. Pham-Thi, N. Roberts, G. Pawankar, R. Rolland, C. Rosario, N. Ryan, D. Samolinski, B. Sanchez-Borges, M. Scadding, G. Shamji, M.H. Sheikh, A. Sturm, G.J. Todo Bom, A. Toppila-Salmi, S. Valentin-Rostan, M. Valiulis, A. Valovirta, E. Ventura, M.-T. Wahn, U. Walker, S. Wallace, D. Waserman, S. Yorgancioglu, A. Zuberbier, T. the ARIA Working Group
- Abstract
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2019
10. 2019 ARIA Care pathways for allergen immunotherapy [ARIA-Versorgungspfade für die Allergenimmuntherapie 2019]
- Author
-
Bousquet, J. Pfaar, O. Togias, A. Schünemann, H.J. Ansotegui, I. Papadopoulos, N.G. Tsiligianni, I. Agache, I. Anto, J.M. Bachert, C. Bedbrook, A. Bergmann, K.C. Bosnic-Anticevich, S. Bosse, I. Brozek, J. Calderon, M. Canonica, G.W. Caraballo, L. Cardona, V. Casale, T. Cecchi, L. Chu, D.K. Costa, E. Cruz, A.A. Czarlewski, W. Durham, S.R. Du Toit, G. Dykewicz, M. Ebisawa, M. Fauquert, J.L. Fernandez-Rivas, M. Fokkens, W.J. Fonseca, J. Fontaine, J.F. Gerth Van Wijk, R. Haahtela, T. Halken, S. Hellings, P.W. Ierodiakonou, D. Iinuma, T. Ivancevich, J.C. Jacobsen, L. Jutel, M. Kaidashev, I. Khaitov, M. Kalayci, O. Kleine Tebbe, J. Klimek, L. Kowalski, M.L. Kuna, P. Kvedariene, V. La Grutta, S. Larenas-Linemann, D. Lau, S. Laune, D. Le, L. Lodrup Carlsen, K. Lourenço, O. Malling, H.J. Marien, G. Menditto, E. Mercier, G. Mullol, J. Muraro, A. O'Hehir, R. Okamoto, Y. Pajno, G.B. Park, H.S. Panzner, P. Passalacqua, G. Pham-Thi, N. Roberts, G. Rolland, C. Rosario, N. Ryan, D. Samolinski, B. Sanchez-Borges, M. Scadding, G. Shamji, M.H. Sheikh, A. Sturm, G.J. Todo Bom, A. Toppila-Salmi, S. Valentin-Rostan, M. Valiulis, A. Valovirta, E. Ventura, M.T. Wahn, U. Walker, S. Wallace, D. Waserman, S. Yorgancioglu, A. Zuberbier, T. ARIA-Arbeitsgruppe
- Abstract
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence- based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. © 2019 Dustri-Verlag Dr. Karl Feistle. All rights reserved.
- Published
- 2019
11. 2019 ARIA Care pathways for allergen immunotherapy
- Author
-
Bousquet, J. and Pfaar, O. and Togias, A. and Schünemann, H.J. and Ansotegui, I. and Papadopoulos, N.G. and Tsiligianni, I. and Agache, I. and Anto, J.M. and Bachert, C. and Bedbrook, A. and Bergmann, K.-C. and Bosnic-Anticevich, S. and Bosse, I. and Brozek, J. and Calderon, M.A. and Canonica, G.W. and Caraballo, L. and Cardona, V. and Casale, T. and Cecchi, L. and Chu, D. and Costa, E. and Cruz, A.A. and Czarlewski, W. and Durham, S.R. and Du Toit, G. and Dykewicz, M. and Ebisawa, M. and Fauquert, J.L. and Fernandez-Rivas, M. and Fokkens, W.J. and Fonseca, J. and Fontaine, J.-F. and Gerth van Wijk, R. and Haahtela, T. and Halken, S. and Hellings, P.W. and Ierodiakonou, D. and Iinuma, T. and Ivancevich, J.C. and Jacobsen, L. and Jutel, M. and Kaidashev, I. and Khaitov, M. and Kalayci, O. and Kleine Tebbe, J. and Klimek, L. and Kowalski, M.L. and Kuna, P. and Kvedariene, V. and La Grutta, S. and Larenas-Linemann, D. and Lau, S. and Laune, D. and Le, L. and Lodrup Carlsen, K. and Lourenço, O. and Malling, H.-J. and Marien, G. and Menditto, E. and Mercier, G. and Mullol, J. and Muraro, A. and O’Hehir, R. and Okamoto, Y. and Pajno, G.B. and Park, H.-S. and Panzner, P. and Passalacqua, G. and Pham-Thi, N. and Roberts, G. and Pawankar, R. and Rolland, C. and Rosario, N. and Ryan, D. and Samolinski, B. and Sanchez-Borges, M. and Scadding, G. and Shamji, M.H. and Sheikh, A. and Sturm, G.J. and Todo Bom, A. and Toppila-Salmi, S. and Valentin-Rostan, M. and Valiulis, A. and Valovirta, E. and Ventura, M.-T. and Wahn, U. and Walker, S. and Wallace, D. and Waserman, S. and Yorgancioglu, A. and Zuberbier, T. and the ARIA Working Group, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U 1168, VIMA : Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States, Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Hospital Quirónsalud Bizkaia, Bilbao, Spain, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Department of Social Medicine, Faculty of Medicine, University of Crete and International Primary Care Respiratory Group, Crete, Greece, Faculty of Medicine, Transylvania University, Brasov, Romania, Centre for Research in Environmental Epidemiology (CREAL), ISGlobAL, Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, ENT Department, Upper Airways Research Laboratory, Ghent University Hospital, Ghent, Belgium, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin Institute of Health, Comprehensive Allergy Centre, Member of GA2LEN, Humboldt-Uniersität zu Berlin, Berlin, Germany, Woolcock Institute of Medical Research, Woolcock Emphysema Centre and Local Health District, University of Sydney, Glebe, NSW, Australia, Allergist, La Rochelle, France, Imperial College London - National Heart and Lung Institute, Royal Brompton Hospital NHS, London, United Kingdom, Personalized Medicine Clinic Asthma & Allergy, Humanitas Research Hospital, Humanitas University, Milan, Italy, Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Cartagena, Colombia, Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Levallois, France, Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom, Guy's and st Thomas' NHS Trust, Kings College London, London, United Kingdom, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, Unité de pneumo-allergologie de l'enfant, pôle pédiatrique, CHU de Clermont-Ferrand-Estaing, Clermont-Ferrand, France, Allergy Department, IdISSC, Hospital Clinico San Carlos, Madrid, Spain, Department of Otorhinolaryngology, Academic Medical Centres, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Allergist, Reims, France, Department of Internal Medicine, Section of Allergology, Erasmus MC, Rotterdam, Netherlands, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Allergy Learning and Consulting, Copenhagen, Denmark, Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland, Ukrainian Medical Stomatological Academy, Poltava, Ukraine, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, National Research Center, Moscow, Russian Federation, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Allergy & Asthma Center Westend, Berlin, Germany, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania, Faculty of Medicine, Institute of Clinical medicine, Clinic of Chest diseases and Allergology, Vilnius University, Vilnius, Lithuania, Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Department of Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Department of Paediatrics, Oslo University Hospital, Oslo, Norway, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Faculty of Health Sciences and CICS – UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Danish Allergy Centre, University of Copenhagen, Copenhagen, Denmark, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Département de l’Information Médicale, Unité Médico-Economie, University Hospital, Montpellier, France, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Allergy and Respiratory Diseases, Ospedale Policlino San Martino -University of Genoa, Genoa, Italy, Allergy Department, Pasteur Institute, Paris, France, David Hide Centre, St Mary's Hospital, Isle of Wight and University of Southampton, Southampton, United Kingdom, Department of Pediatrics, Nippon Medical School, Tokyo, Japan, Association Asthme et Allergie, Paris, France, Hospital de Clinicas, University of Parana, Parana, Brazil, Allergy and Respiratory Research Group, Medical School, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela, The Royal National TNE Hospital, University College London, London, United Kingdom, Immunomodulation and Tolerance Group, Imperial College London, London, United Kingdom, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria, Outpatient Allergy Clinic Reumannplatz, Vienna, Austria, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Allergist, Montevideo, Uruguay, Clinic of Children's Diseases, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, Department of Public Health, Institute of Health Sciences, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Department of Lung Diseases and Clinical Immunology, Terveystalo Allergy Clinic, University of Turku, Turku, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Pediatric Department, Charité, Berlin, Germany, Asthma UK, London, United Kingdom, Nova Southeastern University, Fort Lauderdale, FL, United States, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, and Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
- Abstract
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2019
12. Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications
- Author
-
Kortekaas Krohn, I. (I.), Shikhagaie, M.M. (M. M.), Golebski, K. (K.), Bernink, J.H. (J. H.), Breynaert, C. (C.), Creyns, B. (B.), Diamant, Z. (Zuzana), Fokkens, W.J. (Wytske), Gevaert, P. (P.), Hellings, P.W. (Peter), Hendriks, R.W. (Rudi), Klimek, L. (Ludger), Mjösberg, J.M. (Jenny), Morita, H. (H.), Ogg, G.S. (G. S.), O'Mahony, L. (L.), Schwarze, J. (Jürgen), Seys, S.F. (S. F.), Shamji, M.H. (M. H.), Bal, S.M. (S. M.), Kortekaas Krohn, I. (I.), Shikhagaie, M.M. (M. M.), Golebski, K. (K.), Bernink, J.H. (J. H.), Breynaert, C. (C.), Creyns, B. (B.), Diamant, Z. (Zuzana), Fokkens, W.J. (Wytske), Gevaert, P. (P.), Hellings, P.W. (Peter), Hendriks, R.W. (Rudi), Klimek, L. (Ludger), Mjösberg, J.M. (Jenny), Morita, H. (H.), Ogg, G.S. (G. S.), O'Mahony, L. (L.), Schwarze, J. (Jürgen), Seys, S.F. (S. F.), Shamji, M.H. (M. H.), and Bal, S.M. (S. M.)
- Abstract
Innate lymphoid cells (ILC) represent a group of lymphocytes that lack specific antigen receptors and are relatively rare as compared to adaptive lymphocytes. ILCs play important roles in allergic and nonallergic inflammatory diseases due to their location at barrier surfaces within the airways, gut, and skin, and they respond to cytokines produced by activated cells in their local environment. Innate lymphoid cells contribute to the immune response by the release of cytokines and other mediators, forming a link between innate and adaptive immunity. In recent years, these cells have been extensively characterized and their role in animal models of disease has been investigated. Data to translate the relevance of ILCs in human pathology, and the potential role of ILCs in diagnosis, as biomarkers and/or as future treatment targets are also emerging. This review, produced by a task force of the Immunology Section of the European Academy of Allergy and Clinical Immunology (EAACI), encompassing clinicians and researchers, highlights the role of ILCs in human allergic and nonallergic diseases in the airways, gastrointestinal tract, and skin, with a focus on new insights into clinical implications, therapeutic options, and future research opportunities.
- Published
- 2018
- Full Text
- View/download PDF
13. Biomarker bei der Allergen-Immuntherapie – ein EAACI Positionspapier
- Author
-
Jakwerth, C.A., primary, Shamji, M.H., additional, Kappen, J.H., additional, Akdis, M., additional, Jarolim, E. Jensen-, additional, Knol, E.F., additional, Tebbe, J. Kleine-, additional, Bohle, B., additional, Chaker, A.M., additional, Till, S.J., additional, Valenta, R., additional, Poulsen, L.K., additional, Calderon, M.A., additional, Demoly, P., additional, Pfaar, O., additional, Jacobsen, L., additional, Durham, S.R., additional, and Schmidt-Weber, C.B., additional
- Published
- 2018
- Full Text
- View/download PDF
14. Local allergic rhinitis: Implications for management
- Author
-
Campo, P., primary, Eguiluz‐Gracia, I., additional, Bogas, G., additional, Salas, M., additional, Plaza Serón, C., additional, Pérez, N., additional, Mayorga, C., additional, Torres, M. J., additional, Shamji, M.H., additional, and Rondon, C., additional
- Published
- 2018
- Full Text
- View/download PDF
15. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies
- Author
-
Calderon, M.A. Demoly, P. Casale, T. Akdis, C.A. Bachert, C. Bewick, M. Bilò, B.M. Bohle, B. Bonini, S. Bush, A. Caimmi, D.P. Canonica, G.W. Cardona, V. Chiriac, A.M. Cox, L. Custovic, A. De Blay, F. Devillier, P. Didier, A. Di Lorenzo, G. Du Toit, G. Durham, S.R. Eng, P. Fiocchi, A. Fox, A.T. Van Wijk, R.G. Gomez, R.M. Haathela, T. Halken, S. Hellings, P.W. Jacobsen, L. Just, J. Tanno, L.K. Kleine-Tebbe, J. Klimek, L. Knol, E.F. Kuna, P. Larenas-Linnemann, D.E. Linneberg, A. Matricardi, M. Malling, H.J. Moesges, R. Mullol, J. Muraro, A. Papadopoulos, N. Passalacqua, G. Pastorello, E. Pfaar, O. Price, D. Del Rio, P.R. Ruëff, R. Samolinski, B. Scadding, G.K. Senti, G. Shamji, M.H. Sheikh, A. Sisul, J.C. Sole, D. Sturm, G.J. Tabar, A. Van Ree, R. Ventura, M.T. Vidal, C. Varga, E.M. Worm, M. Zuberbier, T. Bousquet, J.
- Abstract
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. © 2016 The Author(s).
- Published
- 2016
16. Local allergic rhinitis: Implications for management.
- Author
-
Campo, P., Eguiluz‐Gracia, I., Bogas, G., Salas, M., Plaza Serón, C., Pérez, N., Mayorga, C., Torres, M. J., Shamji, M.H., and Rondon, C.
- Subjects
ALLERGIC rhinitis ,IMMUNOGLOBULIN E ,SKIN tests ,PROVOCATION tests (Medicine) ,QUALITY of life ,ASTHMA - Abstract
Summary: A significant proportion of rhinitis patients without systemic IgE‐sensitisation tested by skin prick test and serum allergen‐specific IgE (sIgE) display nasal reactivity upon nasal allergen provocation test (NAPT). This disease phenotype has been termed local allergic rhinitis (LAR). LAR is an underdiagnosed entity affecting children and adults from different parts of the world, with moderate‐to‐severe symptoms, impairment of quality of life and rapid progression to symptom worsening. LAR is a stable phenotype and not merely an initial state of AR. Allergic rhinitis and LAR share many clinical features including a positive NAPT response, markers of type 2 nasal inflammation including sIgE in nasal secretions and a significant rate of asthma development. LAR should be considered as a differential diagnosis in those subjects of any age with symptoms suggestive of AR but no evidence of systemic atopy. Although LAR pathophysiology is partially unknown, in some patients sIgE can be demonstrated directly in the nasal secretions and/or indirectly via positive responses in basophil activation test (BAT). LAR can coexist with other rhinitis phenotypes, especially AR. The diagnosis currently relies on the positivity of NAPT to a single or multiple allergens. NAPT has high sensitivity, specificity and reproducibility, and it is considered the gold standard. BAT and the measurement of nasal sIgE can also contribute to LAR diagnosis. LAR patients benefit from the same therapeutic strategies than AR individuals, including the avoidance of allergen exposure and the pharmacotherapy. Moreover, several recent studies support the effectiveness and safety of allergen immunotherapy for LAR, which opens a window of treatment opportunity in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies
- Author
-
Calderon, M. (Moises), Demoly, P., Casale, T.B. (Thomas), Akdis, C.A., Bachert, C. (Claus), Bewick, M., Bilò, B.M., Bohle, B. (B.), Bonini, S. (Sergio), Bush, A. (Andrew), Caimmi, D.P., Canonica, G. (Gwalter), Cardona, D. (Doris), Chiriac, A.M. (A.), Cox, L. (Linda), Custovic, A. (Adnan), Blay, F. de, Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G. (George), Durham, S.R. (Stephen), Eng, C. (Charis), Fiocchi, A. (Alessandro), Fox, A.T., Gerth van Wijk, R. (Roy), Gomez, R.M., Haathela, T., Halken, S. (Susanne), Hellings, P.W. (Peter), Jacobsen, L., Just, P.M., Tanno, L.K., Kleine-Tebbe, J. (Jörg), Klimek, L. (Ludger), Knol, E.F. (Edward Frank), Kuna, P. (Piotr), Larenas-Linnemann, D. (Désirée), Linneberg, A. (Allan), Matricardi, M., Malling, H.-J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G. (Giovanni), Pastorello, E., Pfaar, O. (Oliver), Price, D. (David), Del Rio, P.R. (P. Rodriguez), Ruëff, R., Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A. (Aziz), Sisul, J.C. (J.), Solé, D. (D.), Sturm, G.J., Tabar, A., Van Ree, R., Ventura, M.T., Vidal, C. (Carmen), Varga, E.M., Worm, M. (M.), Zuberbier, T. (Torsten), Bousquet, J. (Jean), Calderon, M. (Moises), Demoly, P., Casale, T.B. (Thomas), Akdis, C.A., Bachert, C. (Claus), Bewick, M., Bilò, B.M., Bohle, B. (B.), Bonini, S. (Sergio), Bush, A. (Andrew), Caimmi, D.P., Canonica, G. (Gwalter), Cardona, D. (Doris), Chiriac, A.M. (A.), Cox, L. (Linda), Custovic, A. (Adnan), Blay, F. de, Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G. (George), Durham, S.R. (Stephen), Eng, C. (Charis), Fiocchi, A. (Alessandro), Fox, A.T., Gerth van Wijk, R. (Roy), Gomez, R.M., Haathela, T., Halken, S. (Susanne), Hellings, P.W. (Peter), Jacobsen, L., Just, P.M., Tanno, L.K., Kleine-Tebbe, J. (Jörg), Klimek, L. (Ludger), Knol, E.F. (Edward Frank), Kuna, P. (Piotr), Larenas-Linnemann, D. (Désirée), Linneberg, A. (Allan), Matricardi, M., Malling, H.-J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G. (Giovanni), Pastorello, E., Pfaar, O. (Oliver), Price, D. (David), Del Rio, P.R. (P. Rodriguez), Ruëff, R., Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A. (Aziz), Sisul, J.C. (J.), Solé, D. (D.), Sturm, G.J., Tabar, A., Van Ree, R., Ventura, M.T., Vidal, C. (Carmen), Varga, E.M., Worm, M. (M.), Zuberbier, T. (Torsten), and Bousquet, J. (Jean)
- Abstract
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
- Published
- 2016
- Full Text
- View/download PDF
18. Interleukin-35 Suppresses Allergen-specific Th2 Response in Patients with Grass pollen induced Seasonal Allergic Rhinitis
- Author
-
Achkova, D., primary, Chung, F.W., additional, Leyhadi, J.A., additional, Scadding, G.W., additional, Charlesworth, J., additional, Phippard, D., additional, Durham, S., additional, and Shamji, M.H., additional
- Published
- 2012
- Full Text
- View/download PDF
19. Effects of Nasal Allergen Challenge on T cell signature in Peripheral Blood in Patients with Severe Seasonal Allergic Rhinitis
- Author
-
Shamji, M.H., primary, Bellido, V., additional, Scadding, G., additional, Leyhadi, J.A., additional, Calderon, M., additional, Togias, A., additional, Tchao, N., additional, Plaut, M., additional, Turka, L., additional, Phippard, D., additional, and Durham, S., additional
- Published
- 2012
- Full Text
- View/download PDF
20. Frequency Of Grass Pollen-specific Il-4, Il-10 And Dual Il-4 And Il10 Positive Cells In Atopic And Non-atopic Individuals In And Out Of The Pollen Season
- Author
-
Shamji, M.H., primary, Chaker, A., additional, Cheung, D., additional, Poon, M., additional, Schmidt-Weber, C., additional, and Durham, S.R., additional
- Published
- 2011
- Full Text
- View/download PDF
21. IgE-blocking Antibodies may account for a large Proportion of the observed Treatment Effect Induced by Specific Immunotherapy (SIT)
- Author
-
Ljørring, C., primary, Shamji, M.H., additional, Würtzen, P.A., additional, Lund, K., additional, Frew, A.J., additional, Durham, S.R., additional, and Ipsen, H., additional
- Published
- 2009
- Full Text
- View/download PDF
22. Validation of a Functional Assay of IgE-Facilitated CD23-Dependent Allergen Binding to B Cells to Monitor Clinical Efficacy of Immunotherapy
- Author
-
Shamji, M.H., Wilcock, L.K., Larche, M., Francis, J.N., and Durham, S.R.
- Published
- 2006
- Full Text
- View/download PDF
23. Confocal Imaging of Low Affinity IgE Receptor Distribution on B cells: Effects of Grass Pollen Immunotherapy.
- Author
-
Shamji, M.H., Barkans, J.R., Francis, J.N., Kimber, I., and Durham, S.R.
- Published
- 2008
- Full Text
- View/download PDF
24. Management of anaphylaxis due to COVID-19 vaccines in the elderly
- Author
-
Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology
- Subjects
Male ,Allergy ,Pediatrics ,Eaaci Position Paper ,COVID-19 vaccines ,older (adults ,GUIDELINES ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Medicine and Health Sciences ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,Geriatrics ,MESH: Aged ,RISK ,Vaccines ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,people) ,EPINEPHRINE ,Epinephrine ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,COVID -19 vaccines ,Anaphylaxis ,medicine.drug ,older (adults/people) ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,MESH: Covid-19 ,MESH: Epinephrine ,Immunology ,adrenaline ,anaphylaxis ,Aged ,COVID-19 Vaccines ,Humans ,SARS-CoV-2 ,COVID-19 ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,03 medical and health sciences ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Diabetes mellitus ,Anaphylaxis/etiology ,MESH: SARS-CoV-2 ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,COVID‐19 vaccines ,Older - Adults/people ,Asthma ,MESH: Humans ,business.industry ,adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people) ,medicine.disease ,Obesity ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,MESH: Male ,MESH: Anaphylaxis ,Older ,3121 General medicine, internal medicine and other clinical medicine ,business ,MESH: Covid-19 vaccines ,030215 immunology - Abstract
Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion
- Published
- 2021
25. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy
- Author
-
Bousquet, Jean, Pfaar, Oliver, Agache, Ioana, Bedbrook, Anna, Akdis, Cezmi A, Canonica, Giorgio Walter, Chivato, Tomas, Al-Ahmad, Mona, Rasib, A. H. Abdul, Ansotegui, Ignacio J, Bachert, Claus, Soto-Martinez, Manuel, Laune, Daniel, Casale, Tomas, Levin, Michael, Larenas-Linnemann, Désirée, Samolinski, Boleslaw, Lodrup Carlsen, Karin C, O'Mahony, Liam, Lombardi, Carlo, Riggioni, Carmen, Hossny, Elham, Barata, Luís Taborda, Lourenço, Olga, Devillier, Philippe, Mahboub, Bassam, Malling, Hans-Jørgen, Sheikh, Aziz, Manning, Patrick, Passalacqua, Giovanni, Marshall, Gailen D, Sanchez-Borges, Mario, Toppila-Salmi, Sanna, Melén, Erik, Fokkens, Wytske J, Meltzer, Eli O, Miculinic, Neven, Soto-Quiros, Manuel, Milenkovic, Branislava, Roberts, Graham, Ohta, Ken, Scichilone, Nicola, Moin, Mostafa, Odemyr, Mikaëla, Montefort, Stephen, Almeida, Mário Morais, Bom, Ana Todo, Mortz, Charlotte G, Serpa, Faradiba S, Patella, Vincenzo, Sova, Milan, Mösges, Ralph, Mullol, Joaquim, Namazova Baranova, Leyla, Tsiligianni, Ioanna, Neffen, Hugo, Bjermer, Leif, Rodriguez-Gonzales, Monica, Torres, Maria J, Okamoto, Yoshitaka, Okubo, Kimi, Pajno, Giovanni B, Baharuddin, Abdullah, Cecchi, Lorenzo, Sastre, Joaquin, Untersmayr, Eva, Pawankar, Ruby, Pham-Thi, Nhân, Plavec, Davor, Cardona, Victoria, Dokic, Dejan, Sisul, Juan Carlos, Rosario, Nelson, Rottem, Menachem, Rouadi, Philip W, Del Giacco, Stefano, Fonseca, Joao A, Schwarze, Jürgen, Scadding, Glenis K, Shamji, Mohamed H, Schmid-Grendelmeier, Peter, Niedoszytko, Marek, Valentin-Rostan, Marylin, Sofiev, Mikhail, Solé, Dirceu, Sooronbaev, Talant, Palkonen, Susanna, Urrutia-Pereira, Marilyn, Skypala, Isabel, Suppli-Ulrik, Charlotte, Bonini, Matteo, Popov, Todor A, Tomazic, Peter-Valentin, Valero, Antonio, Cepeda Sarabia, Alfonso M, Ryan, Dermot, Bosnic-Anticevich, Sinthia, Valiulis, Arunas, Durham, Stephen L, Schünemann, Holger, Kalayci, Omer, Valovirta, Erkka, Panzner, Petr, Vandenplas, Olivier, Ventura, Maria Teresa, Gotua, Maia, Vichyanond, Pakit, Chkhartishvili, Ekaterine, Wagenmann, Martin, Fontaine, Jean-François, Kull, Inger, Wallace, Dana, Recto, Marysia, Walusiak-Skorupa, Jolanta, Wang, De Yun, Hrubiško, Martin, Waserman, Susan, Ebisawa, Motohiro, Bosse, Isabelle, Grisle, Ineta, Wong, Gary Wk, Bindslev-Jensen, Carsten, Yorgancioglu, Arzu, Yusuf, Osman M, Khaitov, Musa, Zernotti, Mario, Gawlik, Radoslaw, Chu, Derek K, Irani, Carla, Zhang, Luo, Zidarn, Mihaela, Zuberbier, Torsten, Kuna, Piotr, Jutel, Marek, Guzmán, Maria Antonieta, El-Gamal, Yehia, Klimek, Ludger, Brough, Helen A, Brussino, Luisa, Calderon, Moises A, Caraballo, Luis, O'Hehir, Robyn E, Gelincik, Asli, Kvedariene, Violeta, Cirule, Ieva, Cruz, Alvaro A, Czarlewski, Wienczyslawa, Nekam, Kristof, Papadopoulos, Nikolaos G., Haahtela, Tari, Emuzyte, Regina, Gamkrelidze, Amiran, Fauquert, Jean Luc, Palomares, Oscar, Regateiro, Frederico S, Ivancevich, Juan Carlos, Gemicioglu, Bilun, Gereda, Jose E, Gerth van Wijk, Roy, Bergmann, Karl-Christian, Knol, Edward, Halken, Susanne, Heffler, Enrico, Hoffmann-Sommergruber, Karin, Martins, Pedro Carreiro, Kritikos, Vicky, Ispayeva, Zhanat, Julge, Kaja, Kaidashev, Igor, Demoly, Pascal, Kowalski, Marek, Kraxner, Helga, Ollert, Markus, Fiocchi, Alessandro, Lauerma, Antti, Lau, Susanne, Park, Hae-Sim, Gomez, R Maximiliano, Comprehensive Health Research Centre (CHRC) - pólo NMS, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), uBibliorum, Bousquet J., Pfaar O., Agache I., Bedbrook A., Akdis C.A., Canonica G.W., Chivato T., Al-Ahmad M., Abdul Latiff A.H., Ansotegui I.J., Bachert C., Baharuddin A., Bergmann K.-C., Bindslev-Jensen C., Bjermer L., Bonini M., Bosnic-Anticevich S., Bosse I., Brough H.A., Brussino L., Calderon M.A., Caraballo L., Cardona V., Carreiro-Martins P., Casale T., Cecchi L., Cepeda Sarabia A.M., Chkhartishvili E., Chu D.K., Cirule I., Cruz A.A., Czarlewski W., del Giacco S., Demoly P., Devillier P., Dokic D., Durham S.L., Ebisawa M., El-Gamal✝ Y., Emuzyte R., Gamkrelidze A., Fauquert J.L., Fiocchi A., Fokkens W.J., Fonseca J.A., Fontaine J.-F., Gawlik R., Gelincik A., Gemicioglu B., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gotua M., Grisle I., Guzman M.-A., Haahtela T., Halken S., Heffler E., Hoffmann-Sommergruber K., Hossny E., Hrubisko M., Irani C., Ivancevich J.C., Ispayeva Z., Julge K., Kaidashev I., Kalayci O., Khaitov M., Klimek L., Knol E., Kowalski M.L., Kraxner H., Kull I., Kuna P., Kvedariene V., Kritikos V., Lauerma A., Lau S., Laune D., Levin M., Larenas-Linnemann D.E., Lodrup Carlsen K.C., Lombardi C., Lourenco O.M., Mahboub B., Malling H.-J., Manning P., Marshall G.D., Melen E., Meltzer E.O., Miculinic N., Milenkovic B., Moin M., Montefort S., Morais-Almeida M., Mortz C.G., Mosges R., Mullol J., Namazova Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Ollert M., O'Mahony L., Ohta K., Okamoto Y., Okubo K., Pajno G.B., Palomares O., Palkonen S., Panzner P., G Papadopoulos N., Park H.-S., Passalacqua G., Patella V., Pawankar R., Pham-Thi N., Plavec D., Popov T.A., Recto M., Regateiro F.S., Riggioni C., Roberts G., Rodriguez-Gonzales M., Rosario N., Rottem M., Rouadi P.W., Ryan D., Samolinski B., Sanchez-Borges✝ M., Serpa F.S., Sastre J., Scadding G.K., Shamji M.H., Schmid-Grendelmeier P., Schunemann H.J., Sheikh A., Scichilone N., Sisul J.C., Sofiev M., Sole D., Sooronbaev T., Soto-Martinez M., Soto-Quiros M., Sova M., Schwarze J., Skypala I., Suppli-Ulrik C., Taborda-Barata L., Todo-Bom A., Torres M.J., Valentin-Rostan M., Tomazic P.-V., Valero A., Toppila-Salmi S., Tsiligianni I., Untersmayr E., Urrutia-Pereira M., Valiulis A., Valovirta E., Vandenplas O., Ventura M.T., Vichyanond P., Wagenmann M., Wallace D., Walusiak-Skorupa J., Wang D.Y., Waserman S., Wong G.W.K., Yorgancioglu A., Yusuf O.M., Zernotti M., Zhang L., Zidarn M., Zuberbier T., Jutel M., HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Department of Pathology, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Philipps Universität Marburg = Philipps University of Marburg, Transilvania University of Brasov, Universität Zürich [Zürich] = University of Zurich (UZH), Humanitas University [Milan] (Hunimed), Universidad San Pablo CEU, Kuwait University, Al-Rashed Allergy Center [Kuwait City], Pantai Hospital [Kuala Lumpur], Hospital Quirónsalud Bizkaia [Bilbao], Ghent University Hospital, Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Sun Yat-Sen University [Guangzhou] (SYSU), Universiti Sains Malaysia (USM), Humboldt University Of Berlin, Berlin Institute of Health (BIH), Odense University Hospital (OUH), Skane University Hospital [Lund], Fondazione Policlinico Universitario Agostino Gemelli IRCCS, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Woolcock Institute of Medical Research [Sydney], The University of Sydney, Guy's and St Thomas' Hospital [London], King‘s College London, Università degli studi di Torino = University of Turin (UNITO), University of Cartagena, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], Universidad Simon Bolivar (USB), David Tvildiani Medical University (DTMU), McMaster University [Hamilton, Ontario], Children's Clinical University Hospital [Riga, Latvia] (CCUH), Universidade Federal da Bahia (UFBA), Università degli Studi di Cagliari = University of Cagliari (UniCa), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Foch [Suresnes], Sagamihara National Hospital [Kanagawa, Japan], Université Ain Shams, Vilnius University [Vilnius], CHU Clermont-Ferrand, IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Universidade do Porto = University of Porto, Silesian Medical University, Katowice, Poland, Cerrahpasa Faculty of Medicine, Istanbul University, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Universidad de Chile = University of Chile [Santiago] (UCHILE), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Medizinische Universität Wien = Medical University of Vienna, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Tartu University Hospital [Tartu, Estonia], Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Hacettepe University = Hacettepe Üniversitesi, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Siriraj Hospital, Mahidol University, Mahidol University [Bangkok], Nova Southeastern University (NSU), Nofer Institute of Occupational Medicine (NIOM), National University of Singapore (NUS), Yong Loo Lin School of Medicine [Singapore], The Chinese University of Hong Kong [Hong Kong], Manisa Celal Bayar University, Universidad Nacional de Villa María, Universidad Católica de Córdoba, Beijing Tongren Hospital, Herrada, Anthony, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (MGD) Service de pneumologie
- Subjects
Pulmonary and Respiratory Medicine ,precision medicine ,education ,Immunology ,Review ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,immune system diseases ,HDE ALER ,allergic rhinitis ,asthma ,immunotherapy ,Medicine and Health Sciences ,Immunology and Allergy ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,ComputingMilieux_MISCELLANEOUS ,Rhinitis ,RC581-607 ,respiratory tract diseases ,3121 General medicine, internal medicine and other clinical medicine ,Immunologic diseases. Allergy ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,allergic rhinitis, asthma, immunotherapy, precision medicine - Abstract
Funding Information: BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. Funding Information: NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. Funding Information: CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, scibase, advisory role in Sanofi/Regeneron, grants from Glakso Smith‐Kline, advisory role in scibase. Funding Information: MJTreports grants from European Commission, SEAIC, ISCIII, personal fees from Diater laboratory, Leti laboratory, Aimmune Therapeutics. Funding Information: LK reports grants and personal fees from Allergopharma, MEDA/Mylan, LETI Pharma, Sanofi, grants from Stallergenes, Quintiles, ASIT biotech, grants from ALK Abelló, Lofarma, AstraZeneca, GSK, Inmunotk, personal fees from Allergy Therapeut., HAL Allergie, Cassella med; and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. Funding Information: DPreports grants and personal fees from GlaxoSmithKline, personal fees from Menarini, Pliva, Belupo, AbbVie, Novartis, MSD, Chiesi, Revenio, personal fees and non‐financial support from Boehringer Ingelheim, non‐financial support from Philips. Funding Information: OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline, grants from Biomay, Circassia, Pohl‐Boskamp, Inmunotek S.L., personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS. Copyright: Copyright 2021 Elsevier B.V., All rights reserved. publishersversion published
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.